AngioDynamics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of AngioDynamics with a Buy rating and $19 price target. AngioDynamics is a commercial-stage medical technology and device company that focuses on restoring healthy blood flow in the body’s vascular system as well as expanding cancer treatment options to improve patients’ quality of life, the analyst tells investors in a research note. The firm believes the company’s Med Tech segment could continue to grow at an annual rate around 20% in the coming years.